Results 211 to 220 of about 316,007 (306)

Effect of esomeprazole on the pharmacokinetics of vepdegestrant, a PROteolysis TArgeting Chimera oestrogen receptor degrader, in healthy participants

British Journal of Clinical Pharmacology, EarlyView.
Aims The aim of this study is to evaluate the effects of multiple doses of esomeprazole, a strong proton pump inhibitor and acid‐reducing agent, on the pharmacokinetics and safety of vepdegestrant, a PROteolysis TArgeting Chimera oestrogen receptor degrader.
Lana Tran, Naihan Chen, Jennifer A. Winton, Kyle T. Matschke, Smita P. Goodman, Kimberly C. Lee, Yuanyuan Zhang, Weiwei Tan   +7 more
wiley   +1 more source

Inavolisib-Based Therapy for PIK3CA-Mutated Advanced Male Breast Cancer: A Cost-Effectiveness Analysis. [PDF]

Breast Cancer (Dove Med Press)
Huang X, Lin S, Lin R, Luo S, Huang P, Zeng D.   +5 more
europepmc   +1 more source

Marine silicon for biomedical sustainability

BMEMat, EarlyView.
Schematic illustrating marine silicon for biomedical engineering. Abstract Despite momentous divergence from oceanic origin, human beings and marine organisms exhibit elemental homology through silicon utilization. Notably, silicon serves as a critical constituent in multiple biomedical processes.
Yahui Han, Zhibo Yang, Wei Xia, Chengtie Wu   +3 more
wiley   +1 more source

Racial and ethnic disparities and socioeconomic determinants of male breast cancer mortality in the United States. [PDF]

Breast Cancer Res Treat
Freeman JQ, Schechter K, Nguyen LC, Omoleye OJ, Hara JH.   +4 more
europepmc   +1 more source

Polymorphisms, endogenous hormone levels and familial breast cancer risk in premenopausal women [PDF]

, 2010
Johnson, N., Fletcher, O., Gibson, L, Dowsett, M, Silva, ID, Fletcher, O, Moss, S., Hillier, S. G., Peto, J, Johnson, N, Folkerd, E, Silva, I. dos Santos, Walker, K, Moss, S, Hillier, SG, Gibson, L., Palles, C, Walker, K., Palles, C., Folkerd, E., Peto, J., Dowsett, M.   +21 more
core   +1 more source

Harnessing ferroptosis from multilayer defense networks to nanoplatforms for specific cancer therapy

BMEMat, EarlyView.
Nanomaterials target metabolically‐regulated ferroptosis for cancer therapy. Iron‐based or alternative nanoplatforms integrate ferroptosis with chemotherapy, immunotherapy, or radiotherapy. They enable stimulus‐responsive therapies (photothermal, photodynamic, sonodynamic) activated by near‐infrared, light, or ultrasound, achieving potent synergistic ...
Xinyue Xu, Xuejian Wang, Wenyan Jiang, Wan Hairul Anuar Kamaruddin, Chunyan Fang, Pengfei Zhang   +5 more
wiley   +1 more source

High Mortality in the Male Breast Cancer Community: A Report on Its Drivers and a Demand for Change in Healthcare Policy. [PDF]

Cureus
Pasumarthy S, Miller P, Ambrose C, Washburn P, Das Roy L.   +4 more
europepmc   +1 more source

A nanoplatform that induces dual‐amino acid deprivation to reverse tumor immunosuppression and enhance metabolic immunotherapy

BMEMat, EarlyView.
ZIF‐8‐based nanoparticles co‐delivering CB‐839 (glutaminase inhibitor) and 1‐MT (IDO1 inhibitor), dual‐targeting glutamine/tryptophan metabolism to induce immunogenic cell death, activate STING, block kynurenine production, reverse immunosuppression, and enhance cancer immunotherapy to suppress primary/distant tumors.
Wenli Ning, Yunhan Sun, Mingyang Li, Shilu Liu, Fangjie Yi, Hongfei Wang, Ruibing Bai, Dongdong Liu, Fen Zhao, Guiqiang Zhang, Xiao Fu   +10 more
wiley   +1 more source

A case report of male breast cancer treated with breast-conserving surgery. [PDF]

Int J Surg Case Rep
Yoneyama K, Nakagawa M, Hara A.
europepmc   +1 more source